How can immunology contribute to the control of tuberculosis?

Nature Reviews Immunology

Volumn 1, Issue 1, 2001, Pages 20-30

  Kaufmann, Stefan H E ^a  

^a MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

ANIMAL; BIOLOGICAL MODEL; DISEASE MODEL; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; PATHOGENICITY; REVIEW; T LYMPHOCYTE; TUBERCULOSIS;

ANIMALS; BCG VACCINE; DISEASE MODELS, ANIMAL; HUMANS; MICE; MODELS, IMMUNOLOGICAL; MYCOBACTERIUM TUBERCULOSIS; T-LYMPHOCYTES; TUBERCULOSIS;

EID: 0035495579     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/35095558     Document Type: Review

References (122)

1. Kaufmann, S. H. E. Is the development of a new tuberculosis vaccine possible? Nature Med. 6, 955-950 (2000).
2. World Health Organisation. The World Health Report 2000. Health Systems: Improving Performance (WHO, Geneva, 2000).
3. Cole, S. T. et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393, 537-544 (1998). This seminal paper, describing the M. tuberculosis genome, provides the blueprint for the identification of antigens, virulence factors and so on of the pathogen.
4. Cole, S. T. & Barrell, B. G. Analysis of the genome of Mycobacterium tuberculosis H37Rv. Novartis Found. Symp. 217, 160-172 (1998).
5. Ramakrishnan, L., Federspiel, N. A. & Falkow, S. Granuloma-specific expression of Mycobacterium virulence proteins from the glycine-rich PE-PGRS family. Science 288, 1435-1439 (2000).
6. Manabe, Y. C. & Bishai, W. R. Latent Mycobacterium tuberculosis - persistence, patience, and winning by waiting. Nature Med. 6, 1327-1329 (2000).
7. Schaible, U. E., Collins, H. L. & Kaufmann, S. H. Confrontation between intracellular bacteria and the immune system. Adv. Immunol. 71, 257-377 (1999).
8. Ernst, J. D. Macrophage receptors for Mycobacterium tuberculosis. Infect. Immun. 66, 1277-1281 (1998).
9. Ehlers, M. R. & Daffe, M. Interactions between Mycobacterium tuberculosis and host cells: are mycobacterial sugars the key? Trends Microbiol. 6, 328-335 (1998).
10. Gatfield, J. & Pieters, J. Essential role for cholesterol in entry of mycobacteria into macrophages. Science 288, 1647-1650 (2000).
11. Armstrong, J. A. & Hart, P. D. Phagosome-lysosome interactions in cultured macrophages infected with virulent tubercle bacilli: reversal of the usual nonfusion pattern and observations on bacterial survival. J. Exp. Med. 142, 1-16 (1975).
12. Brightbill, H. D. et al. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 285, 732-736 (1999).
13. Schorey, J. S., Carroll, M. C. & Brown, E. J. A macrophage invasion mechanism of pathogenic mycobacteria. Science 277, 1091-1093 (1997).
14. Thoma-Uszynski, S. et al. Induction of direct antimicrobial activity through mammalian toll-like receptors. Science 291, 1544-1547 (2001).
15. Russell, D. G., Dant, J. & Sturgill-Koszycki, S. Mycobacterium avium- and Mycobacterium tuberculosis-containing vacuoles are dynamic, fusion-competent vesicles that are accessible to glycosphingolipids from the host cell plasmalemma. J. Immunol 156, 4764-4773 (1996).
16. Harth, G. & Horwitz, M. A. An inhibitor of exported Mycobacterium tuberculosis glutamine synthetase selectively blocks the growth of pathogenic mycobacteria in axenic culture and in human monocytes: extracellular proteins as potential novel drug targets. J. Exp. Med. 189, 1425-1435 (1999).
17. Ferrari, G., Langen. H., Naito, M. & Pieters, J. A coat protein on phagosomes involved in the intracellular survival of mycobacteria. Cell 97, 435-447 (1999).
18. Lounis, N. et al. Iron and Mycobacterium tuberculosis infection. J. Clin. Virol. 20, 123-126 (2001).
19. Andrews, N. C. Iron metabolism: iron deficiency and iron overload. Annu. Rev. Genomics Hum. Genet. 1, 75-98 (2000).
20. Collins, H. L. & Kaufmann, S. H. E. The many faces of the host response to tuberculosis. Immunology 103, 1-9 (2001).
21. Schaible, U. E., Sturgill-Koszycki, S., Schlesinger, P. H. & Russell, D. G. Cytokine activation leads to acidification and increases maturation of Mycobacterium avium-containing phagosomes in murine macrophages. J. Immunol 160, 1290-1296 (1998).
22. MacMicking, J. D. et al. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc. Natl Acad. Sci. USA 94, 5243-5248 (1997).
23. Rich, E. A. et al. Mycobacterium tuberculosis (MTB)-stimulated production of nitric oxide by human alveolar macrophages and relationship of nitric oxide production to growth inhibition of MTB. Tubercle Lung Dis. 78, 247-255 (1997).
24. Nathan, C. & Shiloh, M. U. Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proc. Natl Acad. Sci. USA 97, 8841-8848 (2000).
25. Kaufmann, S. H. E. in Fundamental Immunology 4th edn (ed. Paul. W.) 1335-1371 (Lippincott-Raven, New York, 1999).
26. McKinney, J. D. et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 406, 735-738 (2000).
27. Weber, I., Fritz, C., Ruttkowski, S., Kreft, A. & Bange, F. C. Anaerobic nitrate reductase (narGHJI) activity of Mycobacterium bovis BCG in vitro and its contribution to virulence in immunodeficient mice. Mol. Microbiol. 35, 1017-1025 (2000).
28. Kaufmann, S. H. E. γ/δ and other unconventional T lymphocytes: what do they see and what do they do? Proc. Natl Acad. Sci. USA 93, 2272-2279 (1996).
29. Schaible, U. E. & Kaufmann, S. H. E. CD1 and CD1-restricted T cells in infections with intracellular bacteria. Trends Microbiol. 8, 419-425 (2000).
30. Lin, Y. G., Zhang, M., Hofman, F. M., Gong, J. H. & Barnes, P. F. Absence of a prominent Th2 cytokine response in human tuberculosis. Infect. Immun. 64, 1351-1356 (1996).
31. Orme, I. M., Roberts, A. D., Griffin, J. P. & Abrams, J. S. Cytokine secretion by CD4 T lymphocytes acquired in response to Mycobacterium tuberculosis infection. J. Immunol. 151, 518-525 (1993).
32. Flynn, J. L. & Chan, J. Immunology of tuberculosis. Annu. Rev. Immunol. 19, 93-129 (2001).
33. Aderem, A. & Ulevitch, R. J. Toll-like receptors in the induction of the innate immune response. Nature 406, 782-787 (2000).
34. Means, T. K. et al. Human toll-like receptors mediate cellular activation by Mycobacterium tuberculosis. J. Immunol. 163, 3920-3927 (1999).
35. Cooper, A. M. et al. Disseminated tuberculosis in interferon-γ gene-disrupted mice. J. Exp. Med. 178, 2243-2247 (1993).
36. Flynn, J. L. et al. Tumor necrosis factor-α is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2, 561-572 (1995).
37. Bean, A. G. et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J. Immunol. 162, 3504-3511 (1999).
38. Mohan, V. P. et al. Effects of tumor necrosis factor-α on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect. Immun. 69, 1847-1855 (2001).
39. Roach, D. R. et al. Secreted lymphotoxin-α is essential for the control of an intracellular bacterial infection. J. Exp. Med. 193, 239-246 (2001). This paper elegantly shows the vital role of lymphotoxin-α in the formation and maintenance of tuberculous granulomas.
40. Feldmann, M. et al. Anti-TNF-α therapy of rheumatoid arthritis: what have we learned? Annu. Rev. Immunol. 19, 163-196 (2001).
41. Maini, R. et al. Infliximab (chimeric anti-tumour necrosis factor-α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 354, 1932-1939 (1999).
42. Myrvik, Q. N., Leake, E. S. & Wright, M. J. Disruption of phagosomal membranes of normal alveolar macrophages by the H37Rv strain of Mycobacterium tuberculosis. A correlate of virulence. Am. Rev. Respir. Dis. 129, 322-328 (1984).
43. Teitelbaum, R. et al. Mycobacterial infection of macrophages results in membrane-permeable phagosomes. Proc. Natl Acad. Sci. USA 96, 15190-15195 (1999).
44. Beatty, W. L. et al. Trafficking and release of mycobacterial lipids from infected macrophages. Traffic 1, 235-247 (2000).
45. Neyrolles, O. et al. Lipoprotein access to MHC class I presentation during infection of murine macrophages with live mycobacteria. J. Immunol. 166, 447-457 (2001).
46. Schaible, U. E., Hagens, K., Fischer, K., Collins, H. L. & Kaufmann, S. H. E. Intersection of group I CD1 molecules and mycobacteria in different intracellular compartments of dendritic cells. J. Immunol. 164, 4843-4852 (2000).
47. 2. J. Immunol. 167, 2187-2192 (2001).
48. Yrlid, U. & Wick, M. J. Salmonella-induced apoptosis of infected macrophages results in presentation of a bacteria-encoded antigen after uptake by bystander dendritic cells. J. Exp. Med. 191, 613-624 (2000).
49. Fayyazi, A. et al. Apoptosis of macrophages and T cells in tuberculosis associated caseous necrosis. J. Pathol. 191, 417-425 (2000).
50. Kaufmann, S. H. E. Killing vs suicide in antibacterial defence. Trends Microbiol. 7, 59-61 (1999).
51. Stenger, S. et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 282, 121-125 (1998).
52. Stenger, S. et al. Differential effects of cytolytic T cell subsets on intracellular infection. Science 276, 1684-1687 (1997). References 51 and 52 convincingly show the capacity of cytolytic T cells to directly curb mycobacterial growth.
53. Oddo, M. et al. Fas ligand-induced apoptosis of infected human macrophages reduces the viability of intracellular Mycobacterium tuberculosis. J. Immunol. 160, 5448-5454 (1998).
54. 7) receptors. Immunity 7, 433-444 (1997).
55. Flynn, J. L., Goldstein, M. M., Triebold, K. J., Koller, B. & Bloom, B. R. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc. Natl Acad. Sci. USA 89, 12013-12017 (1992).
56. 2-microglobulin-dependent resistance to Mycobacterium tuberculosis. Eur. J. Immunol. 31, 1944-1949 (2001).
57. Behar, S. M. et al. Susceptibility of mice deficient in CD1D or TAP1 to infection with Mycobacterium tuberculosis. J. Exp. Med. 189, 1973-1980 (1999).
58. 2microglobulin-dependent mechanisms.
59. Dow, S. W. et al. Immunization with f-Met peptides induces immune reactivity against Mycobacterium tuberculosis. Tubercle Lung Dis. 80, 5-13 (2000).
60. Chun, T. et al. Induction of M3-restricted cytotoxic T lymphocyte responses by N-formylated peptides derived from Mycobacterium tuberculosis. J. Exp. Med. 193, 1213-1220 (2001).
61. + T cells reactive with Mycobacterium tuberculosis-infected antigen-presenting cells. J. Exp. Med. 187, 1633-1640 (1998).
62. + T lymphocytes: The relative contribution of classical versus nonclassical HLA restriction. J. Immunol. 165, 925-930 (2000).
63. Park, S. H. & Bendelac, A. CD1-restricted T-cell responses and microbial infection. Nature 406, 788-792 (2000).
64. Porcelli, S. A. & Modlin, R. L. The CD1 system: antigen-presenting molecules for T cell recognition of lipids and glycolipids. Annu. Rev. Immunol. 17, 297-329 (1999).
65. Ulrichs, T. & Porcelli, S. A. CD1 proteins: targets of T cell recognition in innate and adaptive immunity. Rev. Immunogenet. 2, 416-432 (2000).
66. Sugita, M. et al. CD1c molecules broadly survey the endocytic system. Proc. Natl Acad. Sci. USA 97, 8445-8450 (2000).
67. Stenger, S., Niazi, K. R. & Modlin, R. L. Down-regulation of CD1 on antigen-presenting cells by infection with Mycobacterium tuberculosis. J. Immunol. 161, 3582-3588 (1998).
68. D'Souza, C. et al. An anti-inflammatory role for γδ T lymphocytes in acquired immunity to Mycobacterium tuberculosis. J. Immunol. 158, 1217-1221 (1997).
69. Ladel, C. H. et al. Contribution of α/β T lymphocytes to immunity against Mycobacterium bovis Bacille Calmette-Guérin: studies with T cell receptor-deficient mutant mice. Eur. J. Immunol. 25, 838-846 (1995).
70. Behr-Perst, S. I. et al. Phenotypically activated γδ T lymphocytes in the peripheral blood of patients with tuberculosis. J. Infect. Dis. 180, 141-149 (1999).
71. Dieli, F. et al. Vγ9/Vδ2 T lymphocytes reduce the viability of intracellular Mycobacterium tuberculosis. Eur. J. Immunol. 30, 1512-1519 (2000).
72. Orme, M., McMurray, D. N. & Belisle, J. T. Tuberculosis vaccine development: recent progress. Trends Microbiol. 9, 115-118 (2001).
73. McKinney, J. D. In vivo veritas: the search for TB drug targets goes live. Nature Med. 6, 1330-1333 (2000).
74. Lowrie, D. B. et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 400, 269-271 (1999). This paper shows the value of naked-DNA vaccination in the immunotherapy of tuberculosis.
75. Palmer, C. E. & Long, M. W. Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis. Am. Rev. Respir. Dis. 94, 553-568 (1966).
76. Stanford, J. L., Shield, M. J. & Rook, G. A. How environmental mycobacteria may predetermine the protective efficacy of BCG. Tubercle 62, 55-62 (1981).
77. Dascher, C. C. et al. Conservation of a CD1 multigene family in the guinea pig. J. Immunol. 163, 5478-5488 (1999).
78. McMurray, D. N. A nonhuman primate model for preclinical testing of new tuberculosis vaccines. Clin. Infect. Dis. 30, S210-S212 (2000).
79. Walsh, G. P. et al. The Philippine cynomolgus monkey (Macaca fasicularis) provides a new nonhuman primate model of tuberculosis that resembles human disease. Nature Med. 2, 430-436 (1996).
80. Langermans, J. A. M. et al. Divergent effect of BCG vaccination on Mycobacterium tuberculosis infection in highly related macque species: Implications for primate models in tuberculosis vaccine research. Proc. Natl Acad. Sci. USA (in the press).
81. Wilson, W. et al. Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization. Proc. Natl Acad. Sci. USA 96, 12833-12838 (1999). This paper provides the first description of microarrays for the global analysis of tuberculosis.
82. Kaufmann, S. H. E. From genome to function. Microb. Infect. 3, 811-840 (2001).
83. Relman, D. A. & Falkow, S. The meaning and impact of the human genome sequence for microbiology. Trends Microbiol. 9, 205-208 (2001).
84. Fine, P. E. The BCG story: lessons from the past and implications for the future. Rev. Infect Dis. 11, S353-S359 (1989).
85. Fine, P. E. M. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346, 1339-1345 (1995).
86. Van Rie, A. et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N. Engl. J. Med. 341, 1174-1179 (1999). By unequivocally showing reinfection of patients with M. tuberculosis after cure of primary infection, this paper emphasizes that natural infection fails to induce complete protection in susceptible individuals.
87. Teitelbaum, R. et al. A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival. Proc. Natl Acad. Sci. USA 95, 15688-15693 (1998).
88. Collins, H. L. & Kaufmann, S. H. E. Prospects for better tuberculosis vaccines. Lancet Infect. Dis. 1, 21-28 (2001).
89. Barry, C. E. Interpreting cell wall 'virulence factors' of Mycobacterium tuberculosis. Trends Microbiol. 9, 237-241 (2001).
90. Tascon, R. E. et al. Vaccination against tuberculosis by DNA injection. Nature Med. 2, 888-892 (1996).
91. Huygen, K. et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nature Med. 2, 893-898 (1996). References 90 and 91 were the first to document the value of naked-DNA vaccination in tuberculosis vaccination.
92. Zügel, U. & Kaufmann, S. H. E. Immune response against heat shock proteins in infectious diseases. Immunobiology 201, 22-35 (1999).
93. Steinhoff, U. et al. Autoimmune intestinal pathology induced by hsp60-specrfic CD8 T cells. Immunity 11, 349-358 (1999).
94. Turner, O. C. et al. Lack of protection in mice and necrotizing bronchointerstitial pneumonia with bronchiolitis in guinea pigs immunised with vaccines directed against the hsp60 molecule of Mycobacterium tuberculosis. Infect. Immun. 68, 3674-3679 (2000).
95. Hoffman, S. L., Rogers, W. O., Carucci, D. J. & Venter, J. C. From genomics to vaccines: malaria as a model system. Nature Med. 4, 1351-1353 (1998).
96. Melby, P. C. et al. Identification of vaccine candidates for experimental visceral leishmaniasis by immunisation with sequential fractions of a cDNA expression library. Infect. Immun. 68, 5595-5602 (2000).
97. Skeiky, Y. A. W. T cell expression cloning of a Mycobacterium tuberculosis gene encoding a protective antigen associated with the early control of infection. J. Immunol. 165, 7140-7149 (2000).
98. Olsen, A. W., van Pinxteren, L. A. H., Okkels, L. M., Rasmussen, P. B. & Andersen, P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Infect. Immun. 69, 2773-2778 (2001).
99. Vogel, F. R. Improving vaccine performance with adjuvants. Clin. Infect. Dis. 30, S266-S270 (2000).
100. Hess, J. et al. Mycobacterium bovis Bacille Calmette-Guérin strains secreting listeriolysin of Listeria monocytogenes. Proc. Natl Acad. Sci. USA 95, 5299-5304 (1998).
101. Hess, J., Schaible, U., Raupach, B. & Kaufmann, S. H. E. Exploiting the immune system: toward new vaccines against intracellular bacteria. Adv. Immunol. 75, 1-88 (2000).
102. Murray, P. J., Aldovini, A. & Young, R. A. Manipulation and potentiation of antibacterial immunity using recombinant Bacille Calmette-Guérin strains that secrete cytokines. Proc. Natl Acad. Sci. USA 93, 934-939 (1996).
103. + T cells of mycobacteria growing in human macrophages. Science 260, 984-986 (1993).
104. Hmama, Z., Gabathuler, R., Jefferies, W. A., de Jong, G. & Reiner, N. E. Attenuation of HLA-DR expression by mononuclear phagocytes infected with Mycobacterium tuberculosis is related to intracellular sequestration of immature class II heterodimers. J. Immunol. 161, 4882-4893 (1998).
105. Ting, L. M., Kim, A. C., Cattamanchi, A. & Ernst, J. D. Mycobacterium tuberculosis inhibits IFN-γ transcriptional responses without inhibiting activation of STAT1. J. Immunol. 163, 3898-3906 (1999).
106. Brooks, J. V., Frank, A. A., Keen, M. A., Belisle, J. T. & Orme, I. M. Boosting vaccine for tuberculosis. Infect. Immun. 69, 2714-2717 (2001).
107. Tanghe, A. et al. Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag 85 by protein boosting. Infect. Immun. 69, 3041-3047 (2001).
108. + T-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect. Immun. 69, 681-686 (2001).
109. Feng, C. G. et al. Priming by DNA immunization augments protective efficacy of Mycobacterium bovis Bacille Calmette-Guérin against tuberculosis. Infect. Immun. 69, 4174-4176 (2001).
110. Jungblut, P. R. et al. Comparative proteome analysis of Mycobacterium tuberculosis and Mycobacterium bovis BCG strains: towards functional genomics of microbial pathogens. Mol. Microbiol. 33, 1103-1117 (1999). The first description of the mycobacterial proteome provides a further means for the identification of antigens, virulence factors and so on.
111. Behr, M. A. et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284, 1520-1523 (1999). This paper used DNA microarray analysis to identify the genes lost in attenuation of BCG, providing a comprehensive list of genes that are absent in BCG and present in M. tuberculosis, which constitute potential candidate antigens for vaccination.
112. Horwitz, M. A., Lee, B. W. E., Dilton, B. J. & Harth, G. Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 92, 1530-1534 (1995).
113. Brandt, L., Elhay, M., Rosenkrands, I., Lindblad, E. & Andersen, P. ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect. Immun. 68, 791-795 (2000).
114. Coler, R. N. et al. Vaccination wtih the T cell antigen Mtb 8.4 protects against challenge with Mycobacterium tuberculosis. J. Immunol. 166, 6227-6235 (2001).
115. Hess, J. et al. Protection against murine tuberculosis by an attenuated recombinant Salmonella typhimurium vaccine strain that secretes the 30-kDa antigen of Mycobacterium bovis BCG. FEMS Immunol. Med. Microbiol. 27, 283-289 (2000).
116. Berthet, F. X. et al. Attenuation of virulence by disruption of the Mycobacterium tuberculosis erp gene. Science 282, 759-762 (1998).
117. Yuan, Y. et al. The 16-KDa-crystallin (ACR) protein of Mycobacterium tuberculosis is required for growth in macrophages. Proc. Natl Acad. Sci. USA 95, 9578-9583 (1998).
118. Glickman, M. S., Cox, J. S. & Jacobs, W. R. A novel mycolic acid cyclopropane synthetase is required for coding, persistence, and virulence of Mycobacterium tuberculosis. Mol. Cell 5, 717-727 (2000). Together with reference 26, this paper was among the first publications to describe M. tuberculosis genes that are involved in persistence, and hence constitute interesting targets for the attenuation of the pathogen.
119. Cox, J. S., Chen, B., McNeil, M. & Jacobs, W. R. Jr. Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice. Nature 402, 79-83 (2001).
120. Gukeria, I. et al. Auxotrophic vaccines for tuberculosis. Nature Med. 2, 334-337 (1996).
121. Smith, D. A., Parrish, T., Stoker, N. G. & Bancroft, G. J. Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates. Infect. Immun. 69, 1142-1150 (2001).
122. Horwitz, M. A., Harth, G., Dillon, B. J. & Maslesa-Galic, S. Recombinant Bacillus Calmette-Guérin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc. Natl Acad. Sci. USA 97, 13853-13858 (2000). This paper describes the superior vaccine efficacy of a recombinant BCG that over expresses an antigen already present in wild-type BCG, and provides precedence for improving BCG as a novel vaccine candidate against tuberculosis.